p-ErbB2/HER2 Antibody (12B9): sc-81505

p-Neu Antibody (12B9) is a mouse monoclonal IgG1 antibody that detects Neu in mouse, rat, and human samples through western blotting (WB). p-Neu (12B9) antibody specifically recognizes phosphorylated forms of Neu, which is crucial for understanding Neu′s role in various cellular processes, particularly in cancer biology. Neu, also known as HER2, is a member of the ErbB family of receptor tyrosine kinases and plays a significant role in cell signaling pathways that regulate cell growth, differentiation, and survival. Neu is primarily located at the cell membrane, where Neu interacts with other proteins to form signaling complexes that can lead to oncogenic transformations. Notably, Neu phosphorylation at specific tyrosine residues, such as Tyr 1248, is essential for Neu interaction with the Mucin4/Sialomucin complex, which is localized at the apical surfaces of ductal and alveolar cells in the lactating gland. This localization influences signaling pathways that contribute to the development and progression of certain cancers, including breast, gastric, and esophageal cancers. Using anti-Neu antibody (12B9) in research can provide valuable insights into Neu signaling mechanisms and implications in tumorigenesis, making anti-Neu antibody (12B9) an indispensable tool for cancer research and therapeutic development.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

p-ErbB2/HER2 Antibody (12B9) References:

1. HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1.  |  Bosc, DG., et al. 2001. Oncogene. 20: 6215-24. PMID: 11593430
2. A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia.  |  Huang, TH. and Morrison, SL. 2006. J Pharmacol Exp Ther. 316: 983-91. PMID: 16291729
3. Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.  |  Piechocki, MP., et al. 2007. Cancer Res. 67: 6825-43. PMID: 17638894
4. Protein tyrosine phosphatase epsilon and Neu-induced mammary tumorigenesis.  |  Berman-Golan, D., et al. 2008. Cancer Metastasis Rev. 27: 193-203. PMID: 18231724
5. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis.  |  Khalid, S., et al. 2010. Breast Cancer Res Treat. 122: 647-59. PMID: 19851863
6. Stromal-epithelial interactions modulate cross-talk between prolactin receptor and HER2/Neu in breast cancer.  |  Xu, C., et al. 2012. Breast Cancer Res Treat. 134: 157-69. PMID: 22270933
7. A novel function of HER2/Neu in the activation of G2/M checkpoint in response to γ-irradiation.  |  Yan, Y., et al. 2015. Oncogene. 34: 2215-26. PMID: 24909175
8. Fisetin induces apoptosis in breast cancer MDA-MB-453 cells through degradation of HER2/neu and via the PI3K/Akt pathway.  |  Guo, G., et al. 2019. J Biochem Mol Toxicol. 33: e22268. PMID: 30431692
9. Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues.  |  Tal, M., et al. 1988. Cancer Res. 48: 1517-20. PMID: 3345525
10. Evaluation of the Expression EGFR, HER2/NEU and the End Effector ERK of the RAS/RAF/MAP Kinase Pathway in Prostatic Adenocarcinoma for a Possible Role as New Target Therapy.  |  Shalaby, A., et al. 2024. Asian Pac J Cancer Prev. 25: 2193-2201. PMID: 38918683

The preferred antibody is Antibody (): sc-8.